PML (Promyelocytic Leukemia protein), also known as TRIM19, belongs to the family of tripartite motif (TRIM) proteins. PML is mainly expressed in the nucleus, where it forms dynamic structures known as PML nuclear bodies that recruit many other proteins, such as Sp100 and Daxx. While the role of PML/TRIM19 in antiviral defense is well documented, its effect on HIV-1 infection remains unclear. Here we show that infection by HIV-1 and other retroviruses triggers the formation of PML cytoplasmic bodies, as early as 30 minutes post-infection. Quantification of the number and size of PML cytoplasmic bodies revealed that they last approximately 8 h, with a peak at 2 h post-infection. PML re-localization is blocked by reverse-transcription inhibitors and is not observed following infection with unrelated viruses, suggesting it is specifically triggered by retroviral reverse-transcription. Furthermore, we show that PML interferes with an early step of retroviral infection since PML knockdown dramatically increases reverse-transcription efficiency. We demonstrate that PML does not inhibit directly retroviral infection but acts through the stabilization of one of its well-characterized partners, Daxx. In the presence of PML, cytoplasmic Daxx is found in the vicinity of incoming HIV-1 capsids and inhibits reverse-transcription. Interestingly, Daxx not only interferes with exogenous retroviral infections but can also inhibit retrotransposition of endogenous retroviruses, thus identifying Daxx as a broad cellular inhibitor of reverse-transcription. Altogether, these findings unravel a novel antiviral function for PML and PML nuclear body-associated protein Daxx.
References
[1]
Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, et al. (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848–853. pmid:14985764 doi: 10.1038/nature02343
[2]
Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A 101: 10774–10779. pmid:15249685 doi: 10.1073/pnas.0402361101
[3]
Keckesova Z, Ylinen LM, Towers GJ (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci U S A 101: 10780–10785. pmid:15249687 doi: 10.1073/pnas.0402474101
[4]
Yap MW, Nisole S, Lynch C, Stoye JP (2004) Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci U S A 101: 10786–10791. pmid:15249690 doi: 10.1073/pnas.0402876101
[5]
Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, et al. (2001) The tripartite motif family identifies cell compartments. EMBO J 20: 2140–2151. pmid:11331580 doi: 10.1093/emboj/20.9.2140
[6]
Rajsbaum R, Garcia-Sastre A, Versteeg GA (2014) TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 426: 1265–1284. doi: 10.1016/j.jmb.2013.12.005. pmid:24333484
[7]
Tissot C, Mechti N (1995) Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270: 14891–14898. pmid:7797467 doi: 10.1074/jbc.270.25.14891
[8]
Barr SD, Smiley JR, Bushman FD (2008) The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4: e1000007. doi: 10.1371/journal.ppat.1000007. pmid:18389079
[9]
Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W (2008) TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog 4: e16. doi: 10.1371/journal.ppat.0040016. pmid:18248090
[10]
Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799–808. pmid:16175175 doi: 10.1038/nrmicro1248
[11]
Gao B, Duan Z, Xu W, Xiong S (2009) Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50: 424–433. doi: 10.1002/hep.23011. pmid:19585648
[12]
Eldin P, Papon L, Oteiza A, Brocchi E, Lawson TG, et al. (2009) TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 90: 536–545. doi: 10.1099/vir.0.006288-0. pmid:19218198
[13]
Di Pietro A, Kajaste-Rudnitski A, Oteiza A, Nicora L, Towers GJ, et al. (2013) TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation. J Virol 87: 4523–4533. doi: 10.1128/JVI.02548-12. pmid:23408607
[14]
Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de The H, et al. (2001) PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. Embo J 20: 3495–3505. pmid:11432836 doi: 10.1093/emboj/20.13.3495
[15]
Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK (2006) Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol 80: 8582–8592. pmid:16912307 doi: 10.1128/jvi.00031-06
[16]
Chelbi-Alix MK, Quignon F, Pelicano L, Koken MHM, de The H (1998) Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. J Virol 72: 1043–1051. pmid:9444998
[17]
Blondel D, Kheddache S, Lahaye X, Dianoux L, Chelbi-Alix MK (2010) Resistance to rabies virus infection conferred by the PMLIV isoform. J Virol 84: 10719–10726. doi: 10.1128/JVI.01286-10. pmid:20702643
[18]
Maroui MA, Pampin M, Chelbi-Alix MK (2011) Promyelocytic leukemia isoform IV confers resistance to encephalomyocarditis virus via the sequestration of 3D polymerase in nuclear bodies. J Virol 85: 13164–13173. doi: 10.1128/JVI.05808-11. pmid:21994459
[19]
Mitchell AM, Hirsch ML, Li C, Samulski RJ (2014) Promyelocytic leukemia protein is a cell-intrinsic factor inhibiting parvovirus DNA replication. J Virol 88: 925–936. doi: 10.1128/JVI.02922-13. pmid:24198403
[20]
El Asmi F, Maroui MA, Dutrieux J, Blondel D, Nisole S, et al. (2014) Implication of PMLIV in both intrinsic and innate immunity. PLoS Pathog 10: e1003975. doi: 10.1371/journal.ppat.1003975. pmid:24586174
[21]
Turelli P, Doucas V, Craig E, Mangeat B, Klages N, et al. (2001) Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol Cell 7: 1245–1254. pmid:11430827 doi: 10.1016/s1097-2765(01)00255-6
Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix MK (2013) Differential Roles of PML Isoforms. Front Oncol 3: 125. doi: 10.3389/fonc.2013.00125. pmid:23734343
[24]
Ishov AM, Sotnikov AG, Negorev D, Vladimirova OV, Neff N, et al. (1999) PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J Cell Biol 147: 221–234. pmid:10525530 doi: 10.1083/jcb.147.2.221
[25]
Lallemand-Breitenbach V, de The H (2010) PML nuclear bodies. Cold Spring Harb Perspect Biol 2: a000661. doi: 10.1101/cshperspect.a000661. pmid:20452955
[26]
Bernardi R, Papa A, Pandolfi PP (2008) Regulation of apoptosis by PML and the PML-NBs. Oncogene 27: 6299–6312. doi: 10.1038/onc.2008.305. pmid:18931695
[27]
Everett RD, Chelbi-Alix MK (2007) PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89(6–7): 819–830. pmid:17343971 doi: 10.1016/j.biochi.2007.01.004
[28]
Geoffroy MC, Chelbi-Alix MK (2011) Role of promyelocytic leukemia protein in host antiviral defense. J Interferon Cytokine Res 31: 145–158. doi: 10.1089/jir.2010.0111. pmid:21198351
[29]
Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, et al. (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20: 266–272. pmid:9806545 doi: 10.1038/3073
[30]
Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10: 547–555. doi: 10.1038/ncb1717. pmid:18408733
[31]
Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10(5): 538–546. doi: 10.1038/ncb1716. pmid:18408734
[32]
Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. Embo J 17: 61–70. pmid:9427741 doi: 10.1093/emboj/17.1.61
[33]
Fukuda I, Ito A, Hirai G, Nishimura S, Kawasaki H, et al. (2009) Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol 16: 133–140. doi: 10.1016/j.chembiol.2009.01.009. pmid:19246003
[34]
Dewannieux M, Dupressoir A, Harper F, Pierron G, Heidmann T (2004) Identification of autonomous IAP LTR retrotransposons mobile in mammalian cells. Nat Genet 36: 534–539. pmid:15107856 doi: 10.1038/ng1353
[35]
Ribet D, Dewannieux M, Heidmann T (2004) An active murine transposon family pair: retrotransposition of "master" MusD copies and ETn trans-mobilization. Genome Res 14: 2261–2267. pmid:15479948 doi: 10.1101/gr.2924904
[36]
Borden KL, Campbell Dwyer EJ, Salvato MS (1998) An arenavirus RING (zinc-binding) protein binds the oncoprotein promyelocyte leukemia protein (PML) and relocates PML nuclear bodies to the cytoplasm. J Virol 72: 758–766. pmid:9420283
[37]
Blondel D, Regad T, Poisson N, Pavie B, Harper F, et al. (2002) Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies. Oncogene 21: 7957–7970. pmid:12439746 doi: 10.1038/sj.onc.1205931
[38]
Jin G, Gao Y, Lin HK (2014) Cytoplasmic PML: from molecular regulation to biological functions. J Cell Biochem 115: 812–818. doi: 10.1002/jcb.24727. pmid:24288198
[39]
Carracedo A, Ito K, Pandolfi PP (2011) The nuclear bodies inside out: PML conquers the cytoplasm. Curr Opin Cell Biol 23: 360–366. doi: 10.1016/j.ceb.2011.03.011. pmid:21501958
[40]
Lin HK, Bergmann S, Pandolfi PP (2004) Cytoplasmic PML function in TGF-beta signalling. Nature 431: 205–211. pmid:15356634 doi: 10.1038/nature02783
[41]
McNally BA, Trgovcich J, Maul GG, Liu Y, Zheng P (2008) A role for cytoplasmic PML in cellular resistance to viral infection. PLoS One 3: e2277. doi: 10.1371/journal.pone.0002277. pmid:18509536
[42]
Li H, Leo C, Zhu J, Wu X, O'Neil J, et al. (2000) Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol 20: 1784–1796. pmid:10669754 doi: 10.1128/mcb.20.5.1784-1796.2000
[43]
Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, et al. (2006) Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24: 341–354. pmid:17081986 doi: 10.1016/j.molcel.2006.10.019
[44]
Lindsay CR, Morozov VM, Ishov AM (2008) PML NBs (ND10) and Daxx: from nuclear structure to protein function. Front Biosci 13: 7132–7142. pmid:18508722 doi: 10.2741/3216
[45]
Yang X, Khosravi-Far R, Chang HY, Baltimore D (1997) Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89: 1067–1076. pmid:9215629 doi: 10.1016/s0092-8674(00)80294-9
[46]
Schreiner S, Wodrich H (2013) Virion factors that target Daxx to overcome intrinsic immunity. J Virol 87: 10412–10422. doi: 10.1128/JVI.00425-13. pmid:23864634
[47]
Shalginskikh N, Poleshko A, Skalka AM, Katz RA (2013) Retroviral DNA methylation and epigenetic repression are mediated by the antiviral host protein Daxx. J Virol 87: 2137–2150. doi: 10.1128/JVI.02026-12. pmid:23221555
[48]
Greger JG, Katz RA, Ishov AM, Maul GG, Skalka AM (2005) The cellular protein daxx interacts with avian sarcoma virus integrase and viral DNA to repress viral transcription. J Virol 79: 4610–4618. pmid:15795247 doi: 10.1128/jvi.79.8.4610-4618.2005
[49]
Gurer C, Berthoux L, Luban J (2005) Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol 79: 910–917. pmid:15613319 doi: 10.1128/jvi.79.2.910-917.2005
[50]
Zamborlini A, Coiffic A, Beauclair G, Delelis O, Paris J, et al. (2011) Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect. J Biol Chem 286: 21013–21022. doi: 10.1074/jbc.M110.189274. pmid:21454548
[51]
Huang L, Xu GL, Zhang JQ, Tian L, Xue JL, et al. (2008) Daxx interacts with HIV-1 integrase and inhibits lentiviral gene expression. Biochem Biophys Res Commun 373: 241–245. doi: 10.1016/j.bbrc.2008.06.017. pmid:18558084
[52]
Warren K, Warrilow D, Meredith L, Harrich D (2009) Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription. Viruses 1: 873–894. doi: 10.3390/v1030873. pmid:21994574
[53]
Gao D, Wu J, Wu YT, Du F, Aroh C, et al. (2013) Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341: 903–906. doi: 10.1126/science.1240933. pmid:23929945
[54]
Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, et al. (2013) IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Proc Natl Acad Sci U S A 110: E4571–4580. doi: 10.1073/pnas.1311669110. pmid:24154727
[55]
Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, et al. (2010) A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 467: 214–217. doi: 10.1038/nature09337. pmid:20829794
[56]
Rasaiyaah J, Tan CP, Fletcher AJ, Price AJ, Blondeau C, et al. (2013) HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature 503: 402–405. doi: 10.1038/nature12769. pmid:24196705
[57]
Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, et al. (2013) The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity 39: 1132–1142. doi: 10.1016/j.immuni.2013.11.002. pmid:24269171
[58]
Ishov AM, Vladimirova OV, Maul GG (2004) Heterochromatin and ND10 are cell-cycle regulated and phosphorylation-dependent alternate nuclear sites of the transcription repressor Daxx and SWI/SNF protein ATRX. J Cell Sci 117: 3807–3820. pmid:15252119 doi: 10.1242/jcs.01230
[59]
Kuroki M, Ariumi Y, Ikeda M, Dansako H, Wakita T, et al. (2009) Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. J Virol 83: 2338–2348. doi: 10.1128/JVI.01840-08. pmid:19109388
[60]
Corpet A, Olbrich T, Gwerder M, Fink D, Stucki M (2014) Dynamics of histone H3.3 deposition in proliferating and senescent cells reveals a DAXX-dependent targeting to PML-NBs important for pericentromeric heterochromatin organization. Cell Cycle 13: 249–267. doi: 10.4161/cc.26988. pmid:24200965
